15-hydroxyprostaglandin-I dehydrogenase (NADP+)

15-hydroxyprostaglandin-I dehydrogenase (NADP+), also known as 15-PGDH-I or prostaglandin I2 dehydrogenase, is an enzyme that catalyzes the chemical reaction:

prostaglandin I2 + NADP+ <=> 15-oxo-prostaglandin I2 + NADPH + H+

This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donors with NAD+ or NADP+ as acceptor. It plays a crucial role in the metabolic inactivation of prostaglandin I2 (prostacyclin), a potent vasodilator and inhibitor of platelet aggregation. By converting prostaglandin I2 into 15-oxo-prostaglandin I2, it reduces the biological activity of prostacyclin.

The enzyme is encoded by a gene, and its activity can be influenced by various factors, including genetic variations and environmental conditions. Dysregulation of 15-hydroxyprostaglandin-I dehydrogenase (NADP+) activity has been implicated in various physiological and pathological conditions, including cardiovascular diseases, inflammation, and cancer. Further research is ongoing to fully elucidate its role in these processes and explore its potential as a therapeutic target.